Hepatitis C Inhibitor Compounds

A compound of Formula (I) or a racemate, diastereoisomer, or optical isomer thereof:

• wherein
• B is (C1-10)alkyl, (C3-7)cycloalkyl, or (C1-4)alkyl-(C3-7)cycloalkyl,
• a) wherein said alkyl, cycloalkyl, and alkyl-cycloalkyl may be mono-, di- or tri-substituted with (C1-3)alkyl;
• and
• b) wherein said alkyl, cycloalkyl, and alkyl-cycloalkyl may be mono- or di-substituted with substituents selected from hydroxy and O—(C1-4)alkyl;
• and
• c) wherein each of said alkyl groups may be mono-, di- or tri-substituted with halogen;
• and
• d) wherein each of said cycloalkyl groups being 4-, 5-, 6- or 7-membered having optionally one (for the 4-, 5, 6, or 7-membered) or two (for the 5-, 6- or 7-membered)-CH2-groups not directly linked to each other replaced by —O— such that the O-atom is linked to the group X via at least two C-atoms;
• X is O or NH;
• R3 is (C2-8)alkyl, (C3-7)cycloalkyl or (C1-3)alkyl-(C3-7)cycloalkyl, wherein said alkyl, cycloalkyl, and alkyl-cycloalkyl groups may be mono-, di- or tri-substituted with (C1-4) alkyl;
• L0 is H;
• L1, L2 are each independently halogen, cyano, (C1-4)alkyl, —O—(C1-4)alkyl, —S—(C1-4)alkyl, —SO—(C1-4)alkyl, or —SO2—(C1-4)alkyl, wherein each of said alkyl groups is optionally substituted with from one to three halogen atoms;
• and
• either L1 or L2 (but not both at the same time) may also be H;
• R2 is R20, —NR22COR20, —NR22COOR20—NR22R21 or —NR22CONR21R23, wherein
• R20 is selected from (C1-8)alkyl, (C3-7)cycloalkyl and (C1-4)alkyl-(C3-7)cycloalkyl, wherein said cycloalkyl and alkyl-cycloalkyl may be mono-, di- or tri-substituted with (C1-3)alkyl;
• R21 is H or R20 as defined above,
• R22 and R23 are independently selected from H and methyl,
• R1 is ethyl or vinyl;
• RC is hydroxy or NHSO2RS wherein RS is (C1-6)alkyl, (C3-7)cycloalkyl, (C1-6)alkyl-(C3-7)cycloalkyl, phenyl, naphthyl, pyridinyl, (C1-4)alkyl-phenyl, (C1-4)alkyl-naphthyl or (C1-4)alkyl-pyridinyl;
• each of which optionally being mono-, di- or tri-substituted with substituents selected from halogen, hydroxy, cyano, (C1-4)alkyl, O—(C1-6)alkyl, —CO—NH2, —CO—NH(C1-4)alkyl, —CO—N((C1-4)alkyl)2, —NH2, —NH(C1-4)alkyl and —N((C1-4) alkyl)2, wherein (C1-4)alkyl and O—(C1-6)alkyl are optionally substituted with one to three halogen atoms;
• and each of which optionally being monosubstituted with nitro;
• or RS is —N(RN2)RN1), wherein RN1 and RN2 are independently selected from H, (C1-6)alkyl, (C3-7)cycloalkyl, (C1-6)alkyl-(C3-7)cycloalkyl, aryl and (C1-6)alkyl-aryl;
• wherein said (C1-6)alkyl, (C3-7)cycloalkyl, (C1-6)alkyl-(C3-7)cycloalkyl, aryl and (C1-6)alkyl-aryl are optionally substituted with one or more substituents independently selected from halogen, (C1-6)alkyl, hydroxy, cyano, O—(C1-6)alkyl, —NH2, —NH(C1-4)alkyl, —N((C1-4)alkyl)2, —CO—NH2, —CO—NH(C1-4)alkyl, —CO—N((C1-4)alkyl)2, —COOH, and —COO(C1-6)alkyl;
• or
• RN2 and RN1 are linked, together with the nitrogen to which they are bonded, to form a 3- to 7-membered monocyclic saturated or unsaturated heterocycle or a 9- or 10-membered bicyclic saturated or unsaturated heterocycle, each of which optionally containing from one to three further heteroatoms independently selected from N, S and O, and each of which being optionally substituted with one or more substituents independently selected from halogen, (C1-6)alkyl, hydroxy, cyano, O—(C1-6)alkyl, —NH2, —NH(C1-4)alkyl, —N((C1-4)alkyl)2, —CO—NH2, —CO—NH(C1-4)alkyl, —CO—N((C1-4)alkyl)2, —COOH, and —COO(C1-6)alkyl;
• or a pharmaceutically acceptable salt or ester thereof.